RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Central somatosensory conduction in man: neural generators and interpeak latencies of the far-field components recorded from neck and right or left scalp and earlobes.

Early somatosensory evoked potential (SEP) components to median nerve or finger stimulation were recorded with non-cephalic references in normal young adults. Detailed topographic data over scalp and neck were related to anatomical observations on the actual conduction distances in dorsal column, medial lemniscus and thalamo-cortical parts of the somatosensory pathway. The extrapolation of afferent conduction velocity (CV) measured from sensory nerve potentials along the peripheral nerve to the C6-C7 spinal segments identified the spinal entry time with the onset of the neck N11 or scalp P11 (far field 2 or FF2). The first far field (FF1) is generated in the nerve proximal to axilla. The definite latency shift of the spinal negativity along the neck indicates a CV of 58 m/sec. Data about the maximal diameter of lemniscal axons in man were used to calculate a CV of 40.5 m/sec. Consideration of transit times from spinal entry to cortex and of synaptic delays clarified the arrival times of the afferent volley at various relay nuclei, and also suggested a thalamo-cortical CV of about 33 m/sec. Interpeak and onset-to-peak measures on scalp far fields suggest that FF3-FF4 are generated in medial lemniscus rather than above the thalamus. Consistent differences in amplitude, but not in wave form, were recorded at right and left earlobes for FF2 (larger ipsilaterally) and FF3-FF4 (larger contralaterally). The scalp topography of far fields was analysed in detail.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app